Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AlloNK + obinutuzumab
- Development stage
- Unknown
- Lead developer
- Artiva Biotherapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
AlloNK® + obinutuzumab is an investigational combination therapy developed by Artiva Biotherapeutics for the treatment of autoimmune diseases, including systemic lupus erythematosus (SLE) and lupus nephritis (LN). The combination consists of AlloNK (AB-101), a non-genetically modified, allogeneic, cryopreserved, off-the-shelf natural killer (NK) cell therapy, and obinutuzumab, a type II anti-CD20 monoclonal antibody. The mechanism of action involves AlloNK cells enhancing the antibody-dependent cellular cytotoxicity (ADCC) of obinutuzumab to drive deep depletion of CD20-expressing B cells. This approach aims to provide a potent B-cell targeted therapy without the need for complex genetic engineering or autologous manufacturing. The program is currently being evaluated in a Phase 1 clinical trial (NCT06265220) in patients with active lupus nephritis.
- Brand names
- AlloNK + obinutuzumab
- Other names
- AB-101 + obinutuzumab
02
Targets
CD20 (B-lymphocyte antigen CD20)FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on AlloNK + obinutuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AlloNK + obinutuzumab.